Full-Time
Develops drugs for muscle function disorders
$1 - $350k/hr
Senior, Expert
Remote in USA
Upload your resume to see how it matches 7 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products include small molecule drugs that either enhance or inhibit muscle function, targeting conditions like heart failure, hypertrophic cardiomyopathy, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company is engaged in extensive clinical trials to test these drugs, which include omecamtiv mecarbil and reldesemtiv, among others. Unlike many competitors, Cytokinetics has a strong emphasis on muscle-related therapies and has conducted over 50 clinical trials to ensure the efficacy and safety of its products. The goal of Cytokinetics is to bring effective treatments to market that address the unmet needs of patients suffering from debilitating muscle-related conditions.
Company Size
501-1,000
Company Stage
IPO
Headquarters
South San Francisco, California
Founded
1998
Help us improve and share your feedback! Did you find this helpful?
– Led by new investor Deep Track Capital, with participation from AN Ventures, Catalio Capital Management, Cytokinetics, Inc. and existing investors RA...
Cytokinetics launches EARTH-HCM for hypertrophic cardiomyopathy awareness.
Cytokinetics launches interactive HCM public health tool.
Cytokinetics to present new findings on Aficamten and hypertrophic cardiomyopathy at ACC 2025.
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) - Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 9:00 AM Pacific Time in the Borgia Room of the Westin St. Francis Hotel in San Francisco, CA.